PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.31%
Negative revenue growth while MRVL stands at 4.29%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
2.08%
Gross profit growth at 50-75% of MRVL's 3.82%. Martin Whitman would question if cost structure or brand is lagging.
24.74%
EBIT growth above 1.5x MRVL's 8.09%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
24.74%
Operating income growth above 1.5x MRVL's 15.99%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
587.55%
Positive net income growth while MRVL is negative. John Neff might see a big relative performance advantage.
558.82%
Positive EPS growth while MRVL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
568.75%
Positive diluted EPS growth while MRVL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.89%
Slight or no buybacks while MRVL is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.76%
Diluted share count expanding well above MRVL's 1.17%. Michael Burry would fear significant dilution to existing owners' stakes.
-3.88%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
-9.44%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-26.97%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
41.78%
10Y revenue/share CAGR at 50-75% of MRVL's 56.20%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
2.59%
5Y revenue/share CAGR under 50% of MRVL's 109.65%. Michael Burry would suspect a significant competitive gap or product weakness.
-7.06%
Negative 3Y CAGR while MRVL stands at 25.49%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
37.89%
5Y OCF/share CAGR at 75-90% of MRVL's 45.44%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
31.84%
3Y OCF/share CAGR under 50% of MRVL's 63.72%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
2355.49%
Net income/share CAGR above 1.5x MRVL's 653.69% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
2232.04%
5Y net income/share CAGR above 1.5x MRVL's 220.76%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
780.74%
3Y net income/share CAGR above 1.5x MRVL's 202.86%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
146.09%
5Y equity/share CAGR above 1.5x MRVL's 19.67%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
111.23%
Positive short-term equity growth while MRVL is negative. John Neff sees a strong advantage in near-term net worth buildup.
84.04%
10Y dividend/share CAGR above 1.5x MRVL's 0.04%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
8.03%
Stable or rising mid-term dividends while MRVL is cutting. John Neff sees an edge in consistent payouts vs. the competitor.
39.18%
Our short-term dividend growth is positive while MRVL cut theirs. John Neff views it as a comparative advantage in shareholder returns.
-0.17%
Firm’s AR is declining while MRVL shows 11.24%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
2.85%
Inventory growth well above MRVL's 4.05%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
28.62%
Positive asset growth while MRVL is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
40.37%
Positive BV/share change while MRVL is negative. John Neff sees a clear edge over a competitor losing equity.
-5.41%
We’re deleveraging while MRVL stands at 3.89%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-1.79%
Our R&D shrinks while MRVL invests at 1.74%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-11.65%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.